PDS Biotechnology Refinances Debt with New Note, Warrant

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks PDS Biotechnology ( (PDSB) ) has issued an announcement. On April 30, 2026, PDS Biotechnology entered into a securities purchase agreement with YA II PN, LTD. under which it will issue a $6 million promissory note, sold at a discount, and a warrant for up to 2,158,274 common shares at $1.1824 per share, with closing expected around June 12, 2026 subject to customary conditions including continued Nasdaq listing. The one-year note carries 10% interest, is guaranteed by a subsidiary, restricts new indebtedness and variable-rate financings, and is paired with a new at-the-market offering agreement with Yorkville Securities, while proceeds are expected to help redeem existing senior secured convertible debentures on June 12, 2026 and replace a prior at-the-market program terminated on May 1, 2026. The promissory note includes investor-friendly features such as optional accelerated amortization, conditional conversion at a discount to market if PDS misses payments, and caps on ownership and dilution tied to Nasdaq rules, while the warrant similarly limits exercises to avoid breaching ownership and 19.99% issuance thresholds without shareholder approval. In parallel, PDS plans to register the shares underlying the note and warrant within 30 days of closing and has structured its new at-the-market facility so that cash raised will largely be directed toward servicing and amortizing the new debt, signaling an effort to refinance its capital structure and reduce reliance on its older convertible debentures. On the effective date of the new agreement, PDS delivered irrevocable redemption notices to prepay in cash all outstanding senior secured convertible debentures issued under an April 30, 2025 financing, at 103% of principal plus accrued interest and other amounts due as of the June 12, 2026 redemption date. The company also terminated its prior at-the-market issuance sales agreement with B. Riley Securities and H.C. Wainwright on May 1, 2026, consolidating its equity capital-raising activities under the new arrangement with Yorkville and reworking its balance sheet to reduce legacy secured convertible debt exposure. The most recent analyst rating on (PDSB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page. Spark’s Take on PDSB Stock According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral. The score is primarily held down by weak financial performance (ongoing losses, negative cash flow, and heightened 2025 balance-sheet risk). Offsetting this, the latest earnings call conveyed meaningful clinical and regulatory momentum that could accelerate timelines, while technical indicators are mixed and valuation support is limited due to a negative P/E and no dividend. To see Spark’s full report on PDSB stock, click here. More about PDS Biotechnology PDS Biotechnology Corporation is a Delaware-based biopharmaceutical company focused on developing immunotherapy treatments, with its common stock listed and traded on the Nasdaq Stock Market. The company accesses capital markets through structured financings and at-the-market equity programs to support its operations and manage its debt profile. Average Trading Volume: 726,395 Technical Sentiment Signal: Sell Current Market Cap: $54.31M For an in-depth examination of PDSB stock, go to TipRanks’ Overview page.